On Monday, H.C. Wainwright maintained a positive outlook on Halozyme (NASDAQ:HALO) Therapeutics (NASDAQ:HALO), reiterating its Buy rating and $65.00 price target. The endorsement follows the recent FDA approval of VYVGART Hytrulo, which uses Halozyme's ENHANZE technology, for treating chronic inflammatory demyelinating polyneuropathy (CIDP). This marks the product's second FDA approval, with the first for generalized myasthenia gravis (MG).
The CIDP indication was granted based on the ADHERE study outcomes, where a significant 69% of participants demonstrated clinical improvement. The study underscored a notable 61% reduction in relapse risk compared to a placebo, with a p-value of less than 0.0001, indicating high statistical significance. These findings were a determining factor in the FDA's decision to approve the treatment for CIDP.
The analyst from H.C. Wainwright highlighted the high percentage of trial participants, 99%, who chose to continue with VYVGART Hytrulo in the ADHERE open-label extension. This was seen as a testament to the positive patient experience with the treatment.
The firm's maintained Buy rating and price target are reflective of the confidence in the therapeutic's market potential following this latest regulatory milestone. The analyst's commentary underscores the clinical trial's success and the implications for patient quality of life, mobility, function, and strength.
The $65.00 price target set by H.C. Wainwright for Halozyme Therapeutics is projected over 12 months. This target remains unchanged following the recent FDA approval, as the firm anticipates continued positive developments for the company and its proprietary technology.
In other recent news, Halozyme Therapeutics has been the subject of several significant developments. The company recently secured a new European Union patent for its ENHANZE technology, extending its protection until March 2029. This patent is critical for the protection of DARZALEX SC, a subcutaneous treatment for multiple myeloma, in the EU market.
In terms of financial performance, Halozyme reported strong Q1 results, with a 15% year-over-year royalty growth for the 15th consecutive quarter. The company projects a 10-19% increase in total revenue for the year, amounting to between $915 million and $985 million. EBITDA is anticipated to grow by 26-37%, reaching $535 million to $585 million, while non-GAAP EPS growth is forecasted at 28-41%, resulting in $3.55 to $3.90 per share.
Wells Fargo (NYSE:WFC) also raised its price target to $58, retaining an Overweight rating, while Piper Sandler downgraded the stock from Overweight to Neutral, raising its price target to $51.
InvestingPro Insights
As Halozyme Therapeutics (NASDAQ:HALO) garners analyst confidence with its recent FDA approval, real-time data from InvestingPro fortifies the optimism surrounding the company. With a robust Market Cap of $6.56 billion and a P/E Ratio of 21.02, the financial health of Halozyme is evident. The company's revenue growth is impressive, with a 22.41% increase over the last twelve months as of Q1 2024, reflecting a strong upward trajectory. Additionally, Halozyme's gross profit margin stands at a healthy 69.52%, underscoring the company's efficiency in managing its cost of goods sold.
InvestingPro Tips further illuminate the company's promising position. Analysts have revised their earnings upwards for the upcoming period, signaling confidence in Halozyme's financial future. Moreover, the company's strong return over the last year, with a 51.0% price total return, aligns with the positive outlook presented by H.C. Wainwright. And for those considering a deeper dive into Halozyme's prospects, InvestingPro offers a wealth of additional tips—16 in total—to guide investment decisions. Interested readers can find these on InvestingPro's dedicated page for Halozyme, and don't forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.